Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma

Acta Histochemica

Volumn 116, Issue 1, 2014, Pages 89-93

  Furjelová, Martina ^a   Kovalská, Mária ^a   Jurková, Katarína ^a   Horáček, Jaroslav ^b   Carbolová, Tereza ^b   Adamkov, Marian ^a  

^a Jessenius Faculty of Medicine in Martin and University Hospital Martin   (Slovakia)

^b UNIVERSITY OF OSTRAVA   (Czech Republic)

Author keywords

Breast cancer; Carbonic anhydrase IX; Immunohistochemistry; Tumor biomarker

Indexed keywords

CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; TUMOR ANTIGEN; TUMOR MARKER;

BREAST TUMOR; ENZYMOLOGY; FEMALE; FIBROADENOMA; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARBONIC ANHYDRASES; FEMALE; FIBROADENOMA; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894900393     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.05.009     Document Type: Article

References (38)

1. Bartošová M., Parkkila S., Pohlodek K., Karttunen T.J., Galbavý Š., Mucha V., et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 2002, 197:314-321.
2. Blancher C., Harris A.L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998, 17:187-194.
3. Brennan D.J., Jirstrom K., Kronblad A., Millikan R.C., Landberg G., Duffy M.J., et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2009, 12:21-64.
4. Duffy M.J. Clinical uses of tumour markers: a critical review. Crit Rev Clin Lab Sci 2001, 38:225-262.
5. Generali D., Fox S.B., Berruti A., Brizzi M.P., Campo L., Bonardi S., et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 2006, 13:921-930.
6. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res 1996, 15:1194-1198.
7. Griffiths J.R. Are cancer cell acidic?. Br J Cancer 1991, 64:425-427.
8. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
9. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276.
10. Hussain S.A., Ganesan R., Reynolds G., Gross L., Stevens A., Pastorek J., et al. Hypoxia regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007, 96:104-109.
11. Chia S.K., Wykoff C.H.C., Watson P.H., Han C.H., Leek R.D., Pastorek J., et al. Prognostic significance of novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001, 19:3664-3666.
12. Ilie M., Mazure N.M., Hofman V., Ammadi R.E., Ortholan C., Bonnetaud C., et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomakers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010, 102:1627-1635.
13. Ivanov S.V., Kuzmin I., Wei M.H., Pack S., Geil L., Johnson B.E., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 1998, 95:12596-12601.
14. Kajo K., Žúbor P. Prognostic and predictive factors in breast carcinoma - currently status of knowlegde and its practical contribution. Slov Gynek PÔrod 2010, 17:14651.
15. Kaluz S., Kaluzova M., Opavsky R., Pastorekova S., Gibadulinova A., Dequiedt F., et al. Transcriptional regulation of the MN/CA9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem 1999, 274:32588-32595.
16. Kennedy S.M., O'Driscoll L., Purcell R., Fitz-Simons N., McDermott E.W., Hill A.D., et al. Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88:1077-1083.
17. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79:991-995.
18. Liao S.Y., Stanbridge E.J. Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol Biomar Prev 1996, 5:549-557.
19. Olive P.L., Banáth J.P., Aquino-Parsons C. Measuring hypoxia in solid tumours - is there a gold standard?. Acta Oncol 2001, 40:917-923.
20. Opavský R., Pastoreková S., Zelník V., Gibadulinová A., Stanbridge E.J., Závada J., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33:480-487.
21. Pastorek J., Pastoreková S., Callebaut I., Mornon J.P., Zelník V., Opavský R., et al. Cloning and characterization of MN, a human tumour-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994, 9:2878-2888.
22. Pastoreková S., Kopaček J., Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. J Med Biochem 2007, 7:865-878.
23. Pastorekova S., Parkkila S., Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006, 42:167-216.
24. Pastoreková S., Parkkila S., Parkkila A.K., Opavský R., Zelník V., Saarnio J., et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112:398-408.
25. Pastoreková S., Závada J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Cancer Ther 2004, 2:245-262.
26. Pastoreková S., Zaťovičová M., Pastorek J. Cancer-associated carbonic anhydrase and their inhibition. Curr Pharm Des 2008, 14:685-698.
27. Pichler M., Hutterer G.C., Chromecky T.F., Jesche J., Kampel-Kettner K., Rehak P., et al. Histologic tumor necrosis is an independent prognostic indicator for clear cell and papillary renal cell carcinoma. Am J Clin Pathol 2012, 137:283-289.
28. Potter C., Harris A.L. Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target. Cell Cycle 2004, 3:164-167.
29. Pusztai L, Symmans F. Histopathologic and molecular markers of prognosis and response to therapy. Breast Cancer 2nd Edition 2008;323-39.
30. Saarnio J., Parkkila S., Parkkila A.K., Waheed A., Casey M.C., Zhou X.Y., et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem 1998, 46:497-504.
31. Span P.N., Bussink J., Manders P., Beex L.V., Sweep C.G. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003, 89:271-276.
32. Supuran C.T. Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 2007, 7:825-833.
33. Takáčová M., Bartošová M., Škvarková L., Zaťovičová M., Vidličková I., Csaderová L., et al. CA IX as a clinically significant biomarker associated with renal cell carcinoma. Klinic Urol 2011, 7:28-32.
34. Tomes L., Emberley E., Niu Y., Troup S., Pastorek J., Strange K., et al. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 2003, 81:61-69.
35. 2 tension measurements. Cancer Res 1991, 51:3316-3322.
36. Vleugel M.M., Greijer A.E., Shvarts A., Van der Groep P., Van Berkel M., Aarbodem Y., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 2005, 58:172-177.
37. Wykoff C.H.C., Beasley N., Watson P., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia inducible expression of tumor associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
38. Wykoff C.H.C., Beasley N., Watson P., Campo L., Chia S.K., English R., et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Path 2001, 158:1011-1018.